WHO Medical Device and IVD Prequalification: The Complete Regulatory Guide

What is WHO Prequalification and Why Does It Matter?

The World Health Organization (WHO) Prequalification (PQ) program is a specialized regulatory pathway designed to ensure that key medical products — including vaccines, medicines, vector control products, and In Vitro Diagnostics (IVDs) — meet international standards of quality, safety, and efficacy.

For medical device and IVD manufacturers, WHO Prequalification is not a substitute for standard national registrations (such as FDA clearance or CE marking). Instead, it serves as a critical procurement gatekeeper. Global health funding and procurement agencies — including UNICEF, the Global Fund, the Pan American Health Organization (PAHO), and UNITAID — are legally mandated to purchase only WHO-prequalified products for distribution in low- and middle-income countries (LMICs). Consequently, securing prequalification is essential for manufacturers aiming to access public sector tenders in developing markets.

A scope note: WHO's established, fully operational prequalification programmes cover medicines, vaccines, vector control products, and IVDs. The pathway described below is built on the long-running IVD prequalification programme (launched 2010); broader medical-device assessment is a newer, still-expanding area for which WHO is actively building expert capacity. Manufacturers of general (non-diagnostic) medical devices should confirm current eligibility before investing in a submission.

As the regulatory landscape evolves, WHO has introduced significant procedural changes for 2026. This guide details the prequalification pathway, eligibility requirements, step-by-step submission processes, and the latest regulatory updates.

Eligibility Criteria for WHO Prequalification

Not every medical device or IVD is eligible for the prequalification pipeline. WHO limits its assessment resources to products of high public health priority.

1. Public Health Priority

WHO publishes list-based eligibility criteria. For IVDs, the program focuses primarily on diagnostic assays for high-burden infectious diseases, including:

• HIV (rapid diagnostic tests, enzyme immunoassays, virological monitoring)
• Hepatitis B and C (HBV, HCV)
• Malaria (rapid diagnostic tests)
• Tuberculosis (molecular detection)
• Syphilis (rapid tests)
• Human Papillomavirus (HPV)
• Emerging pathogens (e.g., Ebola, Cholera, Dengue, and pandemic pathogens under emergency listings)

2. Original Manufacturer Status

The applicant must be the actual manufacturer of the product. WHO does not prequalify rebranded or contract-manufactured products where the applicant is merely a distributor or reseller (OEM rebranding). The manufacturing site must have a robust Quality Management System (QMS) aligned with international standards.

3. Commercial Availability

To prevent prequalifying vaporware or prototypes, the product must be commercially available in at least one market at the time of application. Manufacturers must submit proof of sales and regulatory clearances from a recognized reference authority (such as the FDA, EMA, PMDA, or Health Canada).

4. Technical Specifications Series (TSS) Compliance

WHO publishes specific Technical Specifications Series (TSS) documents for each eligible diagnostic analyte. These documents outline the minimum analytical performance, clinical sensitivity, specificity, and operational requirements that the product must meet.

The Prequalification Assessment Pathway: Step-by-Step

The prequalification assessment is a multi-layered process that typically takes between 12 to 24 months, depending on the completeness of the manufacturer's documentation and performance testing.

+-----------------------------------+
|  1. Pre-Submission / Eligibility  |
+-----------------------------------+
                  |
                  v
+-----------------------------------+
|     2. Product Dossier Review     |
+-----------------------------------+
                  |
                  v
+-----------------------------------+
|     3. Performance Evaluation     |
+-----------------------------------+
                  |
                  v
+-----------------------------------+
| 4. Manufacturing Site Inspection  |
+-----------------------------------+
                  |
                  v
+-----------------------------------+
|     5. WHO Prequalification List  |
+-----------------------------------+

Step 1: Pre-Submission and Eligibility Review

Before submitting a formal application, the manufacturer must submit a Pre-Submission Form. WHO reviews this form against current eligibility lists, TSS guidelines, and the regulatory status of the product. If approved, the manufacturer is invited to submit a full product dossier.

Step 2: Product Dossier Review

The manufacturer must submit a comprehensive product dossier compiled using the International Medical Device Regulators Forum (IMDRF) Table of Contents (ToC) format. The dossier must contain detailed technical documentation:

• Design and manufacturing specifications: Raw materials, components, formulation, and manufacturing process flow validation.
• Analytical performance data: In-house validation study reports covering limit of detection (LoD), linearity, precision, cross-reactivity, interfering substances, and specimen stability.
• Clinical performance evidence: Reports from independent clinical trials demonstrating sensitivity and specificity in target populations.
• Stability data: Real-time and accelerated stability study reports for the kit under various environmental conditions (including high humidity/temperature profiles typical of tropical zones).

Step 3: Product Performance Evaluation

The product must undergo independent laboratory testing. WHO coordinates with reference laboratories (e.g., WHO Collaborating Centres) to evaluate a sample of the product. The evaluation tests the product's sensitivity, specificity, and operational ease-of-use using curated panels of clinical specimens.

Step 4: Manufacturing Quality System Inspection

WHO inspectors conduct an on-site audit of the manufacturing facility. The inspection evaluates compliance with ISO 13485:2016 (or equivalent national QMS standards) and specific WHO QMS guidelines. Key focus areas include:

• Traceability of critical raw materials (enzymes, antibodies, primers).
• Process validation for reagent fill-finish, kitting, and packaging.
• Corrective and Preventive Action (CAPA) systems.
• Lot release procedures and quality control testing.

Step 5: Labeling and Instruction for Use (IFU) Review

WHO performs a rigorous review of all product packaging, labels, and Instructions for Use (IFU). The labeling must be clear, legally compliant, and contain precise instructions, warnings, and troubleshooting workflows in multiple official languages (usually English, French, and Spanish).

Key 2026 Prequalification Process Updates

Starting in 2026, WHO is introducing structural modifications to streamline the assessment timeline and align with modern digital submission standards.

1. Decoupling Performance Evaluation

Historically, the product dossier review and independent laboratory performance evaluation were executed in parallel. Under the 2026 guidelines, WHO is separating the performance evaluation from the main prequalification assessment procedure. Performance evaluations will be handled as a pre-requisite or coordinated under independent WHO-accredited testing frameworks, reducing dossier processing bottlenecks at the WHO headquarters.

2. Accelerated Collaborative Registration

WHO has expanded its Collaborative Registration Procedure (CRP). Under this model, if a product is already prequalified by WHO, national regulatory authorities in participating LMICs (such as Kenya, Nigeria, or Bangladesh) can fast-track local registration by relying on WHO's assessment reports, eliminating duplicate technical reviews. WHO's stated aim is for participating NRAs to reach a regulatory decision within a target of about 90 working days, rather than the months or years a standalone national review can take.

WHO Prequalification vs. National Clearances (FDA/CE)

Understanding how WHO Prequalification compares to traditional regulatory pathways is essential for strategic market planning.

Post-Prequalification Obligations

Securing WHO Prequalification is not a one-time achievement. Manufacturers must actively maintain their qualified status through strict post-market compliance:

• Annual Reporting: Manufacturers must submit an annual report detailing production volumes, complaints, adverse events, and a summary of quality control data.
• Change Notifications: Any modification to the product design, critical raw materials, manufacturing process, packaging, or site address must be formally submitted to WHO. Changes are classified as minor (notification only) or major (requiring technical review or re-inspection).
• Post-Market Surveillance (PMS): Active surveillance must be maintained to detect shifts in diagnostic sensitivity or specificity in field settings.
• Re-inspections: WHO schedules periodic re-inspections of manufacturing sites (typically every 3 to 5 years) to ensure ongoing compliance with quality management guidelines.

Strategic Advice for Manufacturers

1. Map Out Tenders First: Before embarking on the costly prequalification process, identify specific global health tenders (UNICEF, Global Fund) for your diagnostic category. Ensure your product aligns directly with their procurement projections.
2. Ensure QMS Maturity: Do not apply if your QMS is immature. WHO audits are highly critical and frequently identify minor non-conformities that can delay the application by several months.
3. Compile Dossiers in IMDRF Format: Standardize your technical files from day one. Using the IMDRF Table of Contents structure simplifies dossier compilation and accelerates WHO reviewer feedback.
4. Engage with WHO Early: Utilize the pre-submission consultation stage to clarify TSS guidelines, performance testing expectations, and eligibility before making a formal submission.